Clinical characteristics, risk factors, and outcomes in Chilean triple negative breast cancer patients: a real-world study-Reference-Cited by-同舟云学术

Clinical characteristics, risk factors, and outcomes in Chilean triple negative breast cancer patients: a real-world study

Published:2022-11-21 Issue:2 Volume:197 Page:449-459
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Acevedo Francisco,Walbaum Benjamín,Medina Lidia,Merino Tomas,Camus Mauricio,Puschel Klaus,Ramírez Karol,Manzor Manuel,Veglia Paulina,Martinez Raúl,Guerra Constanza,Navarro Marisel,Bauerle Catherine,Dominguez Francisco,Sánchez César^ORCID

Funder

Fondecyt

Pfizer

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s10549-022-06814-x.pdf

Reference59 articles.

1. Sung H et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249

2. Nielsen TO et al (2010) A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin cancer Res 16:5222–5232

3. Coates AS et al (2015) Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol 26:1533–1546

4. DeSantis CE et al (2019) Breast cancer statistics, 2019. CA Cancer J Clin 69:438–451

5. Kimura K et al (2012) Association between body mass index and breast cancer intrinsic subtypes in Japanese women. Exp Ther Med 4:391–396

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A contemporary review of breast cancer risk factors and the role of artificial intelligence;Frontiers in Oncology;2024-04-18

2. Real-world data on triple-negative breast cancer in Latin America and the Caribbean;ecancermedicalscience;2023-11-21

3. Suboptimal use of ovarian function suppression in very young women with early breast cancer: a real-world data study;Breast Cancer Research and Treatment;2023-09-21